• English
    • Español
  • Login
Drive Coordinator
  • Log In
Carter BloodCareCarter BloodCareCarter BloodCareCarter BloodCare
  • Donate Blood
    • Blood Donation Process
    • Give Blood Today
    • Eligibility
    • Events
  • Blood Facts
    • Blood Types
    • Types of Donations
    • Blood Use
    • Cholesterol
    • Glossary
  • About Us
    • History
    • Leadership
    • Newsroom
    • Contact
  • Programs
  • You Can Help
    • Donor Guideline FAQs
    • Financial Donation
    • Book a Blood Drive
  • Hospital Partners
  • Give Life
  • Blog
Carter BloodCare Blog
NextPrevious

An Update on Artificial Blood

By Carter BloodCare | 0 comment | Hospital | 23 January, 2020

by Laurie J. Sutor, MD, MBA

The search for a viable alternative to banked human blood for transfusion has been ongoing for nearly 80 years. The ideal blood substitute would be cheaper, stored at room temperature, have a long shelf life, cause no adverse reactions, and be in plentiful supply. We would not have to worry about compatibility for blood types or transmission of infectious diseases. Unfortunately, this scenario remains a pipe dream despite millions of dollars spent over countless years of research.

Red cell substitutes have traditionally fallen into two types: hemoglobin solutions and perfluorochemicals. Hemoglobin solutions have enjoyed modestly more success and have gotten to phase III clinical trials in the U.S., but none have won FDA licensure and none are currently available for routine commercial use in this country.

Hemoglobin solutions could be made from human, animal or recombinant hemoglobin, but all have had various issues with toxicity, rapid clearing from the blood stream, and other adverse events. A 2008 meta-analysis by Natanson et al published in JAMA (299:2304-12) showed a significantly increased risk of death and myocardial infarction in patients getting hemoglobin solutions in an analysis of 16 clinical trials involving five different products. One of these products, Polyheme, made by Northfield Labs from human hemoglobin, had one of the more publicized later trials. Its 2006 clinical trial in trauma patients showed increased mortality in the group getting the red cell substitute. Following this disappointment, and a failed bid for FDA approval, Northfield Labs went out of business in 2009 after more than 20 years of effort on this product.

Another hemoglobin product, Hemopure, made from bovine hemoglobin, has been commercially available for human use in South Africa since 2006 for the treatment of surgical patients who are acutely anemic. It is also approved for commercial sale in Russia for anemia of any etiology. It is available in the U.S. only for investigational or expanded access/compassionate use. Oxyglobin, made by the same company (now called Hemoglobin Oxygen Therapeutics) is FDA and EU approved for veterinary use as a treatment for anemia in dogs. No other hemoglobin solutions are commercially available.

Work continues on the hemoglobin solutions, however, with additional studies planned, and hope persists that further work in cross-linking molecules and encapsulating the hemoglobin will help reduce the problems previously encountered.

The perfluorochemicals (PFCs) work by carrying oxygen in solution. The PFCs are inert and must be dissolved in plasma with an emulsifying agent. The amount of oxygen PFCs carry is proportional to the amount of oxygen to which they are exposed. These compounds have had less success and less attention over the years. Fluosol-DA was a first-generation PFC used in some Jehovah’s Witness patients. It had to be stored frozen and then administered with high levels of oxygen. FDA approved it in 1989, but its production ended in 1994 due to lack of use. Oxygent was a second-generation perfluorochemical that proceeded through phase III trials but was never FDA licensed.

The blood substitutes could serve an excellent niche for patients who cannot get traditional blood transfusion, or for transfusions occurring in austere or remote environments, where storage has its challenges. Although the flurry of activity that occurred in the last half of the twentieth century by many companies has abated in this area, work will likely continue on this front.

artificial blood, blood, blood bank, blood center, blood substitute, Carter BloodCare

Carter BloodCare

More posts by Carter BloodCare

Related Post

  • 1-CBC-0103-COVID-Blog-Header

    COVID-19 and the Blood Supply

    By Carter BloodCare | 25 comments

    We thank you for your interest in donating blood and helping your community. A few eligibility requirements are important to know about during COVID-19. Donation eligibility during COVID-19 You cannot donate if you are inRead more

  • Changes to the 31st Edition of AABB Standards for Blood Banks and Transfusion Services

    By Carter BloodCare | 0 comment

    by Laurie J Sutor, MD, MBA The 31st edition of AABB Standards for Blood Banks and Transfusion Services went into effect on April 1, 2018. There were several changes and additions of note, a fewRead more

  • Quarantines, Recalls, Market Withdrawals and Lookbacks – Video

    By Carter BloodCare | 0 comment

    Confusion frequently arises over the different notifications received from a blood center regarding blood components under suspicion. This video will attempt to clarify the differences between quarantines, recalls, market withdrawals and lookbacks, the different categoriesRead more

  • Quarantines, Market Withdrawals, Recalls, and Lookbacks – a Primer

    By Carter BloodCare | 0 comment

    by L. Sutor, M.D., MBA, Vice President of Medical and Technical Services, Carter BloodCare Confusion frequently arises over the different notifications received from the blood center regarding blood components under suspicion. This article will attempt toRead more

  • What Do You Mean – My Platelets Have Bacteria?

    By Carter BloodCare | 0 comment

    by G. Paranjape, M.D., Medical Director of Clinical Services, Carter BloodCare Carter BloodCare used to perform quality control of apheresis platelets for bacteria by using a test called eBDS. This test allowed us to have aRead more

  • Therapeutic Phlebotomy Programs

    By Carter BloodCare | 10 comments

    If you have Heredity Hemochromatosis or Erythrocytosis/Polycythemia due to testosterone therapy, your physician may recommend blood donation as part of your treatment.  Carter BloodCare has received variances from our regulatory agency, the Food and DrugRead more

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

NextPrevious

Social Icons

Recent Tweets

  • Recent Post
  • Popular Post
  • January 15, 2021
    Give with Confidence
  • January 6, 2021
    Plasma Donations for Treating COVID-19 (Convalescent Plasma)
  • January 5, 2021
    Grand Prairie Donor Center Remodel
  • January 1, 2021
    Whataburger and The Dallas Mavericks thank you for giving blood!
  • December 31, 2020
    Commit to donate blood in 2021
  • May 1, 2016
    The Significance of Being Rh Negative or Rh Positive
  • December 22, 2014
    My Blood Type is AB+
  • November 5, 2014
    What To Do After You Donate
  • July 11, 2016
    Do You Know the Tests Your Blood Goes Through?
  • April 13, 2016
    How Alcohol Affects Your Blood

ABOUT US

With origins in the 1950s, Carter BloodCare is one of Texas' largest blood centers, providing 300,000 units of life-saving blood and blood components to patients in North, Central, and East Texas annually.

NEWSLETTER

Stay connected with the latest information from Carter BloodCare in your local community.

Information

  • Glossary
  • About Us
  • Contact
  • Careers
  • Privacy Policy
  • Glossary
  • About Us
  • Contact
  • Careers
  • Privacy Policy
Copyright 2020 Carter BloodCare | All Rights Reserved
  • Donate Blood
    • Blood Donation Process
    • Give Blood Today
    • Eligibility
    • Events
  • Blood Facts
    • Blood Types
    • Types of Donations
    • Blood Use
    • Cholesterol
    • Glossary
  • About Us
    • History
    • Leadership
    • Newsroom
    • Contact
  • Programs
  • You Can Help
    • Donor Guideline FAQs
    • Financial Donation
    • Book a Blood Drive
  • Hospital Partners
  • Give Life
  • Blog
Carter BloodCare